Role of regulatory T cells in the development of skin diseases

Anais Brasileiros de Dermatologia

Volumn 81, Issue 3, 2006, Pages 269-281

  Lima, Hermênio Cavalcante ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (Brazil)

Author keywords

Dermatology; Skin diseases; T Lymphocytes; T Lymphocytes, suppressor inducer; Therapeutics

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; TACROLIMUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGY; ALOPECIA AREATA; ATOPIC DERMATITIS; AUTOIMMUNITY; CANDIDIASIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CHRONIC INFLAMMATION; CONTACT DERMATITIS; DISEASE COURSE; EFFECTOR CELL; EPSTEIN BARR VIRUS; HERPES; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LEISHMANIASIS; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; PEMPHIGUS VULGARIS; PHENOTYPE; PSORIASIS; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SKIN DISEASE; SKIN INFLAMMATION; SUPPRESSOR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION;

EID: 34248675767     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/s0365-05962006000300010     Document Type: Review

References (121)

1. Nordlind K, Vahlquist A. Nya trender inom immundermatologi och hudterapi. Lakartidningen. 1999.24;96:876-81.
2. Ljubojevic S, Lipozencic J, Brenner S, Budimcic D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol. 2002;16:599-603.
3. Russell-Jones R, Powell AM, Acland K, Calonje E, O'Doherty M, Healy C. The chances of a patient with melanoma developing in transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB). Eur J Surg Oncol. 2005;31:210-1.
4. Brown DW, Baker BS, Ovigne JM, Hardman C, Powles AV, Fry L. Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol. 2000;114:576-80.
5. Ewida AS, Raphael SA, Abbasi JA, Geslani GP, Bagasra O. Evaluation of Th-1 and Th-2 immune responses in the skin lesions of patients with Blau syndrome. Appl Immunohistochem Mol Morphol. 2002;10:171-7.
6. Hertl M, Riechers R. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol. 1999;26:748-52.
7. Rizzo C, Fotino M, Zhang Y, Chow S, Spizuoco A, Sinha AA. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol. 2005;30:535-40.
8. Novak N, Bieber T. The skin as a target for allergic diseases. Allergy. 2000;55:103-7.
9. Horwitz DA, Gray JD, Zheng SG. The potential of human regulatory T cells generated ex vivo as a treatment for l0upus and other chronic inflammatory diseases. Arthritis Res. 2002;4:241-6.
10. Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med. 2002.15; 196:237-46.
11. Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol. 2005;17:638-42.
12. Silverstein AM. Horror Autotoxicus: the concept of autoimmunity. A history of Immunology. San Diego: Academic Press; 1989. p.160-89.
13. Talmage DW. Origins of the cell selection theories of antibody formation. In: Gallagher RB, Gilder J, Nossal GJV, Salvatore G, editors. Immunology: The making of a modern science. London: Academic Press Limited; 1995. p.23-7.
14. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119-21.
15. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med. 1993;177:999-1008.
16. Ramsdell F, Fowlkes BJ. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science. 1990.15;248:1342-8.
17. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science. 1969.7;166:753-5.
18. Sakakura T, Nishizuka Y. Thymic control mechanism in ovarian development: reconstitution of ovarian dysgenesis in thymectomized mice by replacement with thymic and other lymphoid tissues. Endocrinology. 1972;90:431-7.
19. Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun. 1996;9: 211-20.
20. Han HS, Jun HS, Utsugi T, Yoon JW. A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun. 1996;9:331-9.
21. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 2003;112:1310-2.
22. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
23. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology. 1971;21:903-14.
24. Dorf ME, Benacerraf B. Suppressor cells and immunoregulation. Annu Rev Immunol. 1984;2:127-57.
25. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2:816-22.
26. Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol. 2000;18:423-49.
27. Green DR, Webb DR. Saying the 'S' word in public. Immunol Today. 1993;14:523-5.
28. Nagler-Anderson C, Bhan AK, Podolsky DK, Terhorst C. Control freaks: immune regulatory cells. Nat Immunol. 2004;5:119-22.
29. Shevach EM, Thornton A, Suri-Payer E. T lymphocyte-mediated control of autoimmunity. Novartis Found Symp. 1998;215:200-11; discussion 211-30.
30. Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med. 2003;197:451-60.
31. Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, et al. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol. 2002;32:1621-30.
32. Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E. Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology. 2002;106:190-9.
33. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-53.
34. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996;183:2669-74.
35. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-94.
36. Lepault F, Gagnerault MC. Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol. 2000;164:240-7.
37. Curotto de Lafaille MA, Lafaille JJ. CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol. 2002;14:771-8.
38. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-62.
39. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-61.
40. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-6.
41. Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG, Lejon K. CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. J Immunol. 2001;167:4271-5.
42. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389-400.
43. Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol. 2004;16:1189-201.
44. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol. 2001;166:3008-18.
45. Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun. 2001;16:115-23.
46. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol. 2002;129:263-76.
47. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGFbeta signals in vivo. Proc Natl Acad Sci U S A. 2005;102:419-24.
48. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A. 2003;100:10878-83.
49. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002;196:255-60.
50. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002;196:247-53.
51. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003;3:189-98.
52. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207-14.
53. Kumar V. Homeostatic control of immunity by TCR peptide-specific Tregs. J Clin Invest. 2004;114:1222-6.
54. Taams LS, Akbar AN. Peripheral generation and function of CD4+CD25+ regulatory T cells. Curr Top Microbiol Immunol. 2005;293:115-31.
55. Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer JP, Groux H. A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J Immunol. 2003;171:5018-26.
56. Cavani A, Mei D, Guerra E, Corinti S, Giani M, Pirrotta L, et al. Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses. Evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J Invest Dermatol. 1998;111:621-8.
57. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-42.
58. Lecart S, Boulay V, Raison-Peyron N, Bousquet J, Meunier L, Yssel H, et al. Phenotypic Characterization of Human CD4+ Regulatory T Cells Obtained from Cutaneous Dinitrochlorobenzene-Induced Delayed Type Hypersensitivity Reactions. J Invest Dermatol. 2001;117:318-25.
59. Hennino A, Vocanson M, Chavagnac C, Saint-Mezard P, Dubois B, Kaiserlian D, et al. Fisiopatologia da dermatite de contato alérgica: papel das células T CD8 efetoras e das células T CD4 regulatórias. An Bras Dermatol. 2005;80:335-47.
60. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol. 2000;114:295-302.
61. Schafer SC, Ring S, Enk AH, Lehr HA. CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions by blocking influx of effector T cells into inflamed tissue in vivo. J Vasc Res. 2006;43:33.
62. Bellinghausen I, Knop J, Saloga J. The role of regulatory CD4(+) CD25(+) T cells in allergic diseases. Allergologie. 2004;27:444-9.
63. Akbari O, Stock P, DeKruyff RH, Umetsu DT. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol. 2003;15:627-33.
64. Nieves DS, Phipps RP, Pollock SJ, Ochs HD, Zhu Q, Scott GA, et al. Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Arch Dermatol. 2004;140:466-72.
65. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+CD25+ regulatory Tcell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 2004;363:608-15.
66. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine AL, Brunet LR, Kemeny DM, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med. 2002; 8:625-9.
67. Vukmanovic-Stejic M, McQuaid A, Birch KE, Reed JR, Macgregor C, Rustin MH, et al. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Br J Dermatol. 2005;153:750-7.
68. Sugiyama H, Gyulai RP, Shimada S, Cooper KD, Stevens SR, McCormick TS. Decreased suppressive capacity of psoriatic CD4+CD25+ regulatory T cells: a novel mechanism for sustained autoreactivity in psoriasis. J Invest Dermatol. 2002;119:299.
69. Garaczi E, Goodman W, Sugiyama H, Gyulai R, McCormick TS, Cooper KD. Identification of a unique population of regulatory T cells in psoriasis by elimination of transiently activated CD4+CD25+cells. J Invest Dermatol. 2004;122:A120-A.
70. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174:164-73.
71. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+) CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 2001;31:1122-31.
72. Zoller M, McElwee KJ, Engel P, Hoffmann R. Transient CD44 variant isoform expression and reduction in CD4(+)/CD25(+) regulatory T cells in C3H/HeJ mice with alopecia areata. J Invest Dermatol. 2002;118:983-92.
73. Zoller M, McElwee KJ, Vitacolonna M, Hoffmann R. Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients. J Autoimmun. 2004;23:241-56.
74. Zoller M, Freyschmidt-Paul P, Vitacolonna M, McElwee KJ, Hummel S, Hoffmann R. Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata. Clin Exp Immunol. 2004;135:398-408.
75. Rivitti EA. Alopecia areata: revisäo e atualizaçäo. An Bras Dermatol. 2005;80:57-68.
76. McElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124:947-57.
77. Montagnoli C, Bacci A, Bozza S, Gaziano R, Mosci P, Sharpe AH, et al. B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol. 2002;169:6298-308.
78. Walker LSK. CD4+ CD25+ Treg: divide and rule? Immunology. 2004;111:129-37.
79. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2:845-58.
80. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420:502-7.
81. Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, Alexander J, et al. CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol. 2003;170:394-9.
82. Sacks D, Anderson C. Re-examination of the immuno suppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol Rev. 2004;201:225-38.
83. Toews GB, Bergstresser PR, Streilein JW. Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol. 1980;124:445-53.
84. Elmets CA, Bergstresser PR, Tigelaar RE, Wood PJ, Streilein JW. Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J Exp Med. 1983;158:781-94.
85. Schwarz A, Maeda A, Wild MK, Kernebeck K, Gross N, Aragane Y, et al. Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J Immunol. 2004;172:1036-43.
86. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213-22.
87. Fisher MS, Kripke ML. Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science. 1982;216:1133-4.
88. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol. 2000;1:521-5.
89. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003;21:273-6.
90. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005;175:8392-400.
91. Suvas S, Azkur AK, Kim BS, Kumaraguru U, Rouse BT. CD4+CD25+ regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol. 2004; 172:4123-32.
92. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med. 2003;198:889-901.
93. Toka FN, Suvas S, Rouse BT. CD4(+) CD25(+) T cells regulate vaccine-generated primary and memory CD8(+) T-cell responses against herpes simplex virus type 1. J Virol. 2004;78:13082-9.
94. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6:353-60.
95. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-62.
96. Beilharz MW, Sammels LM, Paun A, Shaw K, van Eeden P, Watson MW, et al. Timed ablation of regulatory CD4(+) T cells can prevent murine AIDS progression. J Immunol. 2004;172:4917-25.
97. Tsunemi S, Iwasaki T, Imado T, Higasa S, Kakishita E, Shirasaka T, et al. Relationship of CD4+CD25+regulatory T cells to immune status in HIV-infected patients. AIDS. 2005;19:879-86.
98. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174:4407-14.
99. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004;200:331-43.
100. Nixon DF, Aandahl EM, Michaelsson J. CD4(+)CD25(+) regulatory T cells in HIV infection. Microbes Infect. 2005;7:1063-5.
101. Suvas S, Rouse BT. Regulation of microbial immunity: the suppressor cell renaissance. Viral Immunol. 2005;18:411-8.
102. de Carvalho VO. Diferenças na prevalência de dermatoses inflamatórias e infecciosas conforme a alteração imunológica do paciente pediátrico infectado pelo HIV [tese]. Curitiba: Universidade Federal do Paraná; 2005.
103. da Cruz RC. Cinética dos marcadores laboratoriais de atopia em crianças infectadas pelo HIV [tese]. Curitiba: Universidade Federal do Paraná; 2005. p.70.
104. Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004;172:6468-75.
105. Aoki-Ota M, Kinoshita M, Ota T, Tsunoda K, Iwasaki T, Tanaka S, et al. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol. 2006;126:105-13.
106. Levings AK, Roncarolo MG. Phenotypic and functional differences between human CD4(+)CD25(+) and type 1 regulatory T cells. In: Kyewski B, Suri-Payer E, editors. Cd4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential. Germany: Springer; 2005. p. 303-26.
107. Bushell A, Jones E, Gallimore A, Wood K. The generation of CD25(+)CD4(+) regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol. 2005;174:3290-7.
108. Voltarelli J, Palma P, Morais F, Castro F. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after allo geneic bone marrow transplantation. Biol Blood Marrow Transplant. 2004;10:53-4.
109. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang SW, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;192:681-93.
110. Takayashiki T, Asakura H, Ku G, Kataoka M, Flye MW. Infectious tolerance develops after intrathymic alloantigen-induced acceptance of rat heart allografts can be adoptively transferred. Surgery. 2005;138:254-60.
111. Loser K, Hansen W, Apelt J, Balkow S, Buer J, Beissert S. In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Therapy. 2005;12:1294-304.
112. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4(+)CD25(+) regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971-9.
113. Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med. 2004;199: 1285-91.
114. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol. 2002;32:2237-45.
115. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401-6.
116. Nicholl M, Lodge A, Brown I, Sugg SL. Restored immune response to an MHC-II-restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J Pediatr Surg. 2004;39:941-6.
117. Yu P, Lee Y, Liu WH, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4(+) cells unmasks tumor immunogenicity leading to the rejection of latestage tumors. J Exp Med. 2005;201:779-91.
118. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4(+)CD25(hi) regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018-25.
119. Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H. Inhibition of CD4(+)25(+) T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-8.
120. Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25(+) CD4(+) regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci. 2005;39:105-12.
121. Stock P, Akbari O, DeKruyff RH, Umetsu DT. Respiratory tolerance is inhibited by the administration of corticosteroids. J Immunol. 2005;175:7380-7.